Micreos Pockets €12m For Staphefeckt Products

Antibacterial-focused Micreos has pocketed €12m for the global development of its antibacterial lysin technology, Endolysin Staphefeckt, as a prescription product to suppress Staphylococcus aureus on the skin of individuals with eczema, rosacea and acne.

Antibacterial-focused Micreos has pocketed €12m for the global development of its antibacterial lysin technology, Endolysin Staphefeckt, as a prescription product to suppress Staphylococcus aureus on the skin of individuals with eczema, rosacea and acne.

Staphefeckt in Micreos' Gladskin cream and gel formulations is already on the market in Europe for inflammatory skin conditions with...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Dermatological

More from Therapeutic Category